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WML                -                  white matter lesion
CNS                   -                    Central nervous system
CT                      -                   Computerized Tomogram
MRI                   -                    Magnetic Resonance Imaging
EEG                   -                    Electro Encephalogram
CAA                  -                    Cerebral amyloid angiopathy
CSF                    -                    Cerebrospinal Fluid
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COGNITIVE DYSFUNCTION IN
SMALL VESSEL DISEASE
Abstract
Introduction – cerebral small vessel disease is an important risk factor for
stroke and cognitive dysfunction in the elderly population. Most often small
vessel disease are asymptomatic, presenting as white matter hyperintensities.
Detailed clinical evaluation may reveal cognitive dysfunction. Vascular risk
factors may predispose to the occurence of small vessel disease , as these white
matter changes are believed to be of ischemic in origin.
Aim and objective – To study the clinical cognitive dysfunction in
asymptomatic patients, presenting with white matter hyperintensities. To study
the correlation between the extent of white matter changes,as assessed by
Fazekas visual rating scale and degree of cognitive dysfunction.
Materials and methods – Patients aged more than 40yrs, presenting with white
matter hyperintensity without higher mental function disturbance were included.
Those with MMSE<9, terminal illness, fulfilling criteria for Alzheimers’s
disease and psychiatric illnes were excluded. Toatl of 38 patients were
studied.White matter changes were rated as mild, moderate and severe by
Fasekas visual rating scale. Detailed higher mental function and individual lobar
functions were evaluated and correlation assessed. Various risk factors were
analysed.
Results  - Age is found to be the most important risk factor, and white matter
changes increase with age. Hypertension and smoking were also strong risk
factors. On clinical evaluation, psychomotor slowing was observed in 55% of
patients with small vessel disease. Higher cognitive function like social
judgement, abstract thinking were affected in 47% of patients. Executive
dysfunction and impairment in alternate sequence was noted in 39% of subjects.
Attention was impaired in 37% cases. Memory was involved in 21% of pateints.
On evaluating the MRI changes by visual rating scale, moderate degree of white
matter changes were observed in most of the patients52%. Strong correlation
existed between the severity of white matter changes and psychomotor slowing
and higher cognitive involvement but statistical significance could not be
obtained due to small cohart.
Conclusion – asymptomatic, subclinical involement of cognitive function was
obserevd in patients with cerebral small vessel disease. Psychomotor slowing
and higher cognitive function impairment  were most commonly observed. As
small vessel disease may cause significant impairment in activities of daily
living, primary prevention by attending to the vascular risk factors is the best
way to prevent morbidity in elderly population.
Keywords – cerebral small vessel disease, white matter hyperintensity,
psychomotor slowing, higher cognitive function.
1INTRODUCTION
Cerebral white matter disease, also known as cerebral small vessel
disease1 includes a group of pathological conditions of varied etiology that
affect small arteries, arterioles, venules and capillaries of the brain. Age-
related, hypertension-related and cerebral amyloid angiopathy are the most
common forms of cerebral small vessel disease. The consequences of
small vessel disease on the brain parenchyma are mainly lesions located in
the subcortical structures such as lacunar infarcts, white matter lesions and
microbleeds. Unlike large vessels, small vessels cannot be currently
visualised. Therefore, the parenchymal  lesions that are thought to be
caused by these vessel changes have been adopted as the marker of small
vessel disease. Small vessel disease has an important role in
cerebrovascular disease and is a leading cause of cognitive decline and
functional loss in the elderly.
It was for a long time, that small vessel diseases were regarded as an
incidental ?nding with no therapeutic consequences, but now there is
increasing evidence that it is associated with cognitive decline and a higher
risk of stroke and death 2 . Given this clinical relevance, recent years have
shown a growing interest in small vessel disease, it’s pathology,
epidemiology, risk factors and treatment options. Changes in subcortical
2white matter are common incidental findings on computed tomography
and magnetic resonance imaging (MRI) in healthy elderly subjects3,4.
          In some individuals, MRI white matter hyperintensity represent
small infarcts; in others, there is accumulation of fluid adjacent to
hypertensive vessels, while in still others only white matter pallor is
detected.5-7  Hachinski  et  al8 have coined the term leukoaraiosis (thinning
of cerebal white matter) to describe these white-matter abnormalities. The
clinical significance of these WMLs remains unclear, with some studies
reporting that, they are associated with neuropsychological deficits9,10 and
with others failing to document any relationship between the presence and
severity of white-matter changes and cognitive abnormalities.11-14 Some
studies have shown that white matter lesions are not only associated with
cognitive disorders but also with gait15-17, mood  disturbances,18,19  and
urinary problems.20
Thus small vessel disease presenting as WML are the cause of about
a quarter of all acute ischaemic strokes. 21,22 Overall, strokes caused by
small vessel disease are less severe, but, the long-term outcome of these
patients cannot be thought of as benign in terms of mortality and functional
impairment.23 No speci?c treatment for strokes caused by small vessel
disease in the acute phase has yet been proposed.
3Hence, the study small vessel disease and its correlation with
cognitive dysfunction is useful for future development of new therapeutic
options and search for its risk factors.
   Therefore, it is useful to study white matter lesions on MRI, their
severity and clinical correlation with cognitive dysfunction.
4AIM AND OBJECTIVES
To analyze the cognitive dysfunction in patients with small vessel
disease who manifest as white matter hyperintensities on MRI. To assess
the severity of  white matter lesions on MRI by visual rating scale and to
study whether correlation exists between white matter lesion load and
clinical cognitive dysfunction.
5REVIEW OF LITERATURE
Small vessel diseases are the most frequent pathological
neurological processes24, playing a crucial role in at least three conditions:
stroke, dementia, and ageing. Pathological processes that a?ect the small
vessels of the brain such as small arteries and arterioles, capillaries and
small veins are included under small vessel disease. But most often, small
vessel disease is used to refer only to the arterial vessels.
Cerebral arterial small vessels have two origins: super?cially, they
stem from the subarachnoid circulation as terminal vessels of medium-
sized arteries that originate from larger arteries. Secondly, deeper system at
the base of the brain that stem directly from the large vessels as
perforators. These two systems converge towards each other. After having
passed the cortical layers and the deep grey structures respectively, they
tend to merge in the deepest areas of the subcortical white matter where
there is a watershed area.25 Since the small vessels can not be visualisded,
MRI periventricular hyperintensities are adopted as marker of small vessel
disease.
CLASSIFICATION
          Small vessel diseases are systemic disorders that a?ect various
organs  of  the  body.  In  some  cases,  the  brain  may  be  the   main  target  of
6these diseases, and the lesions and e?ects of the disease may be con?ned to
the brain. In other cases, brain may not be a?ected at all.
There are di?erent types of small vessel diseases and a simpli?ed
aetiopathogenic classi?cation is as follows:
Classification of small vessel disease1
Type 1: Arteriolosclerosis (or age-related and vascular risk-factor-related
small vessel diseases)
Fibrinoid necrosis
Lipohyalinosis
Microatheroma
Microaneurysms (saccular, lipohyalinotic, asymmetric fusiform)
Segmental arterial disorganisation
Type 2: Sporadic and hereditary cerebral amyloid angiopathy
Type 3: Inherited or genetic small vessel diseases
Example - CADASIL, CARASIL, MELAS, Fabry’s disease, hereditary
cerebroretinal vasculopathy, small vessel diseases caused by COL4A1
mutations
Type 4: Inflammatory and immunologically mediated small vessel diseases
7Example- Churg-Strauss syndrome, Wegener’s granulomatosis,
Microscopic polyangiitis, cryoglobulinaemic vasculitis, Henoch-Schönlein
purpura, Primary angiitis of the CNS, Sneddon’s syndrome, Nervous
system vasculitis secondary to infections, nervous system vasculitis
associated with connective tissue disorders such as systemic lupus
erythematosus, Sjogren’s syndrome, rheumatoid vasculitis.
Type 5: venous collagenosis
Type 6: other small vessel diseases
Example - Post-radiation angiopathy and Non-amyloid microvessel
degeneration in Alzheimer’s disease
Among these, type 1, arteriolosclerosis, and type 2, sporadic and
hereditary cerebral amyloid angiopathy  are the most prevalent forms.
Recent reports show that inherited small vessel diseases are in increase.26
Of these diseases, CADASIL (cerebral autosomal dominant arteriopathy
with subcortical ischaemic strokes and leukoencephalopathy) and Fabry’s
disease are among the most prominent.27-29  In?ammatory and
immunologically mediated small vessel diseases are a heterogeneous group
of diseases that are rare and characterised by the presence of in?ammatory
cells in the vessel walls (vasculitis). They usually present as part of a
systemic disease30. Venous collagenosis is pathological appearance of
8venules and veins that are closely located to the lateral ventricles.31 These
vessels have increased thickness of the walls due to collagen that results in
narrowing of the lumen and even occlusion.
The application of CT in the seventies and the subsequent
application of MRI to image the brain have revealed an unexpected
number of changes in the cerebral white matter in both asymptomatic and
cognitively impaired individuals.
The pathogenesis and the clinical significance of these white matter
alterations and its pathological substrate are not completely understood.
The optimal term to designate these changes are also controversial. Some
authors assume that the cerebral white matter changes (demonstrated by
CT or MRI) are synonymous with "Binswanger's disease",  while others
use the term leukoaraiosis to refer to all white matter changes visible on
neuroimaging studies.
HISTORICAL OVERVIEW
In 1894, Otto Binswanger described the case of  syphillis in a  man,
who developed a progressive decline in mental functions characterized by
speech, memory disorder, depression and personality changes with
diminished  motor power in the lower limbs and slight hand tremor.32,33 In
1902 Alzheimer,34,35 attributed the clinical and pathological changes in
9Binswanger’s case was due to white matter changes caused by
arteriosclerosis of the long penetrating vessels. In 1962  J.Olszewski, 36
reviewing Binswanger's original report, proposed the term subcortical
arteriosclerosis in which vessels of the white matter and subcortical grey
matter are affected predominantly.  As on date, the diagnosis of
Binswanger's disease  had acquired new popularity after the introduction of
CT  and  MRI.   But,  it  soon  became  apparent  that  alterations  in  the  white
matter detected by either CT or MRI were common in both symptomatic
and asymptomatic subjects.
PATHOPHYSIOLOGY OF LEUKOARAIOSIS
           Cerebral white matter disease, also called as cerebral small vessel
disease, is reported frequently on neuroimaging, especially in older
patients. It was regarded for a long time as an incidental ?nding, but with
no therapeutic consequences. But now there is increasing evidence that it is
associated with cognitive dysfuction as well as higher risk of stroke and
death.
          Cerebral small vessel disease is one of the common degenerative
vessel disorders in the ageing human brain, along with cerebral
atherosclerosis and cerebral amyloid angiopathy.37 Its pathophysiology is
still not completely understood. Endothelial dysfunction is proposed to
10
play an important role  and is one of the ?rst steps in the development of
small vessel ischaemia. However, a recent review by stevenson et al.,
concluded that endothelial dysfunction  may play  a role in the
development of small vessel disease but  it is unlikely to be speci?c to
small vessel diseases and also occurs in other types of cerebrovascular
disease. Several factors may cause endothelial damage including
mechanical factors like hypertension. Endothelial damage allows plasma
proteins to leak into the vessel wall. This makes the vessel wall swell and
may subsequently cause hyaline degeneration and ?brosis. This in turn
leads to thickening of the wall, narrowing of the vessel lumen, reduced
blood ?ow and cerebral perfusion and ?nally to ischaemia of the tissues
supplied by these vessels.
Tissue injury caused by chronic ischaemia is one of the possible
pathogenetic mechanism involved in the development of white matter
lesions. In addition, endothelial damage leads to breakdown of the
bloodbrain barrier. Plasma components which normally do not permeate
through the bloodbrain barrier can now enter into the interstitial space and
11
brain parenchyma  and cause damage to neurons and glial cells. These
areas of damage in the brain may appear as white matter lesions on
neuroimaging and on histopathological studies. White matter disease may
hence be a consequence of varied pathological processes such as chronic
ischaemia, breakdown of bloodbrain barrier and leakage of potentially
12
neurotoxic  substances  into  the  brain  or  of  combination  of  any  of  these
mechanisms.
          The brains of patients with periventricular leukoaraiosis frequently
show other pathological and imaging changes as well. For example,
leukoaraiosis and lacunar infarcts often coexist.38 Lacunar infarcts are
caused by occlusion of  small perforating vessels and are considered as
another manifestation of small vessel disease even though their
pathophysiology is different  from that of leukoaraiosis. The co-existence
of leukoaraiosis and occlusion of small perforating vessels leading on to
lacunar infarct are associated with higher risk of major stroke in patients
with leukoaraiosis. Enlarged perivascular spaces also known as
VirchoweRobin spaces  are another common ?nding in small vessel
disease and is usually formed  around the diseased vessel.39  On CT brain
images, these enlarged perivascular  spaces may be misdiagnosed as
lacunar infarcts, but can be clearly distinguished on MRImaging. The
clinical signi?cance of enlarged VirchoweRobin space is uncertain.
Cerebral microbleeds are small haemorrhages involving the perivascular
spaces. Pathologically, they represent the leakage of blood and its
components through the vessel wall rather than frank haemorrhage. They
are  frequently seen in association with leukoaraiosis. They are most
commonly found in cases of cerebral amyloid angiopathy, but can also
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occur in patients whose hypertension is poorly controlled.40 The clinical
importance of microbleeds is on increase. Microbleeds may indicate an
increased risk for cerebral haemorrhage, particularly in patients who are on
anticoagulation therapy. Some clinicians even regard cerebral microbleed
as a relative contraindication to anticoagulation therapy. But, data are not
clear on the extent to which cerebral microbleeds increase the risk of
cerebral haemorrhage. Further studies in this area are going on.
Finally, leukoaraiosis may also be associated with brain atrophy.41,42
With increasing severity of white matter disease, there is often associated
corresponding decrease in grey and white matter volume and an increase in
the size of ventricles.43 Grey  matter  atrophy  may  be  caused  by
deafferentation due to loss of cortical-subcortical connections.
Consequently,the ventricles may enlarge due to loss of subcortical white
matter.42
PREVALENCE
The prevalence of leukoaraiosis varies widely between different
studies. The prevalence rates vary from 5.3% 43  to more than 95%.44  This
high variability may be explained by the methodological differences
between various studies, for example different ways for assessing
leukoaraiosis in neuroimaging and differences in the risk factors and
14
comorbidities included in the study populations. With such varied
estimates of the prevalence of leukoaraiosis, it is dif?cult to assess whether
its prevalence has changed over time. However, the data so far available do
not show any significant temporal changes in the prevalence of white
matter disease.
This is surprising, because the better quality and more sensitive
brain imaging available today might have led to a higher rate of diagnosis
in ageing population. This may have led to a real increase in the prevalence
of small vessel disease. But, today the awareness of risk factors are on the
high and control of hypertension has certainly improved. Hence, an
apparent increase in the prevalence of leukoaraiosis because of better
imaging may have been offset by a real decrease due to aggressive blood
pressure control. However, neuroimaging has only been easily and widely
available since 1980s, and  three decades may be too short a time to show
significant changes in the leukoaraiosis prevalence.
RISK FACTORS
Risk factors associated with leukoaraiosis have been studied
extensively and study ?ndings are con?icting probably due to differences
in study methodology adopted. Risk factors may be non-modi?able or
15
acquired and treatable. Hypertension is the strongest modi?able risk factor
for leukoaraiosis. Most widely studied risk factors are discussed below.
Age
          Increasing age is probably the most important risk factor associated
with the development of leukoaraiosis,44,45Hence it is often referred as
‘age-related white matter disease’. Though  leukoaraiosis is a pathological
phenomenon, it may to some extent be a part of the normal physiological
ageing process. But, it is unclear at what age exactly white matter disease
starts developing. Precise data on the extent of disease that can be
considered as ‘normal’ at a particular age do not exist. Most of the studies
suggest that  at least some white matter lesions exist after the age of 50-65
years. It is clear that leukoaraiosis is a common ?nding in the elderly and it
becomes more prevalent and more severe as age increases.
Sex
          Studies analysing the association between the prevalence of
leukoaraiosis and gender shows con?icting results. Some studies found
that  higher prevalence of leukoaraiosis was found in women,46 while some
showed a trend that men are at higher risk.45  Such results may be partly
explained by differences in the characteristics of the study population and
by various confounding factors. There have been differences in the age or
16
the prevalence of hypertension between women and men  suggesting an
apparent sex difference  in the white matter disease prevalence. But a
recent systematic review did not ?nd any such gender differences.
RACE
          White matter disease occurs  more frequently in Afro-Caribbean
than Caucasian populations and this may be because of a higher prevalence
of hypertension in the  Afro-Caribbean.47 And often hypertension is more
severe  and blood pressure control is poorly controlled in afro-caribeans.
Genetic factors may also play a role in such  gender difference.
GENETIC FACTORS
          Genetic disorders like cerebral autosomal dominant arteriopathy
with subcortical infarcts and leukoencephalopathy (CADASIL), are
associated with prominent lesions in the white matter. But, CADASIL
contributes only for a very small number of cases with white matter
disease.53  Several studies have shown that the presence of white matter
lesions and polymorphisms in a number of genes, such as
Apolipoprotein(a) or ACE are associated.60 Such genetic disorders may not
be directly associated with white matter disease but may predispose an
individual to develop risk factors for small vessel disease, as well as their
susceptiblity to develop end-organ damage due to the risk factors. For
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instance, the development of  hypertension to certain extent is determined
genetically, and soforth, the tendency to develop small vessel disease as a
result of hypertension might also be in?uenced by such genetic factors.
HYPERTENSION
Hypertension is one factor that is strongly associated with white
matter disease and is the most important modi?able risk factor so far.25
Studies indicate that elevation of both systolic and diastolic blood pressure
are relevant in increasing the risk for leukoaraiosis. Threshold value above
which the disease starts is not apparent, and the association is found to be a
continuum. Apart from the absolute values, diurnal variation in blood
pressure may also contribute to white matter disease.
DIABETES MELLITUS
          The effect of diabetes mellitus on development of leukoaraiosis has
shown con?icting results. Some studies show a positive association 48  in
particular  with periventricular lesions. Impaired fasting glucose (IFG) was
found to be associated with the development white matter disease. A recent
review comparing diabetics with and without leukoaraiosis found that
higher insulin levels are present in those with white matter disease. All
these data suggest that insulin resistance is a definite risk factor to cause
white matter disease. However, the strength of association is not clear and
18
pathophysiology is uncertain. A few studies have  failed to ?nd any
association.49
DYSLIPIDEMIA
         Dyslipidemia is an important risk factor associated with large vessel
disease. It is unclear whether abnormalities in lipid metabolism are also a
risk factor for white matter disease. Few studies have shown that low high-
density lipoprotein and hypertriglyceridaemia may increase the risk for
developing small vessel disease.50 However, other studies did not ?nd any
association between dyslipidaemia and small vessel disease.51
SMOKING
         It is not clear whether smoking in?uences the development of small
vessel disease. Some studies found that they are associated45  whereas
others found no differences in the prevalence of white matter changes
between smokers and non-smokers.49,51 Smoking predisposes to large
vessel atherosclerosis. But the underlying pathology in leukoaraiosis is
proposed to be disease of the small vessels and hence large vessel
atheroma and leukoariosis may not necessarily be associated. Few studies
have found an association between atherosclerotic disease and white
matter lesions.
19
        This can be explained by two different mechanisms. First, stenosis
caused by atherosclerosis  allows less blood into the brain and lesser
perfusion that increases the risk for chronic ischaemia and hence the risk of
developing white matter lesions. Second, small vessel disease and
atherosclerotic disease have some risk factors in common which may occur
concurrently.
HOMOCYSTEINE AND VITAMIN B12
        Several studies have supported the association between low serum
vitamin B12 levels and small vessel disease, especially those with
periventricular lesions.52 However, though there is some evidence that
hyperhomocysteinaemia, which may be caused by deficiency of vitamin
B12 and low vitamin B12 levels are associated with white matter lesions,
there is yet no data showing that vitamin B12 substitution or lowering
homocysteine improves leukoaraiosis or slows its progression.
         To summarise, hypertension and increasing age are the only well
accepted risk factors for white matter disease. The association between
small vessel disease and other risk factors might be due to confounding by
hypertension. For instance, Afro-Caribbean population  who are more
likely to be hypertensive have higher prevalence of white matter disease.
The association of leukoaraiosis and other factors is less certain. This
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includes diabetes mellitus which is widely believed to increase the risk of
developing small vessel disease. Differences in study methodology can
explain some of the con?icting results.  But  a  recent  systematic review of
so far available data con?rmed age and hypertension are  the only
consistent risk factors for white matter disease and no clear association
exists with any other risk factor.
CLINICAL PRESENTATION
White matter lesions often remain asymptomatic until they affect a
signi?cant quantity of brain tissue.54 Symptoms due to leukoaraiosis
emerge slowly over time, and is often not possible exactly to determine
their onset. Moreover, the symptoms due to white matter disease  are non-
speci?c and may also be attributed  by other pathological conditions that
are also common in ageing population. Frequently, such pathological
conditions may often coexist. For instance, patients may be diagnosed as
‘mixed dementia’ because of having both vascular dementia and
Alzheimer ’s disease. It is henceforth, dif?cult to say at which stage white
matter lesions become symptomatic and which are the speci?c symptoms it
causes.
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           There  is general agreement that leukoaraiosis is associated with
     - Cognitive decline54,55
     - Gait disturbance and falls56,57
     - Depression56
     - Increased stroke risk.
           Among these, decline in cognitive function is the widely recognised
clinical presentation. It may present with poor performance in a gross
range of cognitive tests. Psychomotor slowing, executive dysfunction and
attention impairment are predominantly affected by white matter
lesions.2,54 Additionally, leukoaraiosis is also associated with deterioration
in gait and thus leading to an increased risk of falls.
                    Given the association of white matter lesions with cognitive
dysfunction and gait disturbance, it is not unusual that in elderly
patients,those with larger white matter lesions performed worse in their
activities of daily living than those controls without signi?cant
leukoaraiosis.58
THE ASSOCIATION OF LEUKOARAIOSIS AND STROKE
           White matter lesions and stroke are very closely associated.
Previous history of stroke is associated with higher prevalence of white
22
matter lesions,43 and leukoaraiosis is found to be a risk factor for the ?rst
ever and also for recurrent stroke.2 This association may be explained by
shared risk factors like increasing age, diabetes and hypertension.
Moreover, leukoaraiosis is thought to be due chronic low-level ischaemia.
Chronic ischaemia of brain tissue predisposes to higher risk of
development of infarction if exposed to further insult in the form of
ischaemia. There also exists a close association between white matter
lesions and lacunar stroke. Both are found to be manifestations of cerebral
small vessel disease and may occur together.  Few authors believe that
leukoaraiosis represents chronic ischemic changes whereas lacunar infarcts
are due to an acute insult.  Some authors have shown that  the risk factors
for these two conditions are different and hence suggest they may
represent different pathologies.
IMAGING IN SMALL VESSEL DISEASE
           With advent of newer brain imaging, particularly MRI and its
various sequences,  a multitude of focal, patchy or diffuse signal changes
in the cerebral white matter are demonstrated.59 The MRI changes may be
hyperintense compared with the normal white matter on T2 or FLAIR
sequences, with or without corresponding hypointensity on T1-weighted
images.60 Inspite of extensive research, pathogenic mechanism, clinical
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significance  and structural substrate of these changes are still incompletely
understood.61
           Various studies have shown that on MRI, the frequency of white
matter hyperintensities increases with advancing age.62,63 Risk factors
associated with such white matter changes are hypertension, cardiac
disorders, diabetes mellitus, smoking and cerebrovascular disorders. Such
white matter lesions may present with clinical features like cognitive
dysfunction, gait abnormality or mood disorder. But the results are
conflicting. Some nonspecific white matter changes may exist in clinically
normal healthy individuals.63,64 The distinction between normal white
matter changes and pathological white matter changes may be difficult.
Source of controversy in the previous studies could be due to
different rating scales used to assess the white matter changes. There are
about 13 commonly used MRI rating scales.
          White matter changes may involve periventricular region and/or
deep white matter region. Various visual rating scales have used various
parameters to assess the white matter lesion load.  Periventricular
hyperintensities were rated by The Gerard and Weisberg scale and The
Shimada scale.  Periventricular and deep white matter hyperintensities
were rated by scales like The Erkinjuntti scale, The Fazekas scale, The
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Mirsen scale, The Scheltens scale,  The Ylikoski scale, wahlud scale and
the schimdt scale. Deep white matter hyperintensity scales include The
Herholz scale, The Hunt scale, The van Swieten scale. Mantyala et al65
compared the 13 scales and states that international harmonization of white
matter changes is needed.
SUBCORTICAL DEMENTIA
           Subcortical ischemic vascular dementia is subtype of vascular
dementia that inculcates small-vessel disease as the main pathological
process with ischaemic white-matter lesions and lacunar infarct as the
predominant brain lesions. The location of lesions is primarily subcortical
and subcortical syndrome is the clinical manifestation. Subcortical
dementia is quoted by overlapping clinical entities like Binswanger’s
disease, small vessel disease and the lacunar stroke.66,67 Clinical
identification of subcortical dementia may be based on a modified criteria
of  National  Institute  of  Neurological  Disorders  and  Stroke  and  the
Association Internationale Recherche en Neurosciences (NINDS-AIREN)
for vascular dementia.68  Vascular dementia criteria require that onset of
dementia is related to cerebrovascular disease. In subcortical dementia, the
onset is more insidious and gradually progressive. Temporal relationship
between neuroimaging, cognitive dysfunction, and evidence for
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cerebrovascular disease is not always clear. Hence, the temporal relation
association was omitted from research criteria for subcortical dementia.
The neuroimaging criteria includes patients with predominant whitematter
lesions (Binswanger type) and those with lacunar infarcts (lacunar state
type).68 The classification of subcortical dementia due to white matter
lesions caused by small vessel disease identifies a homogenous group of
patients with predictable clinical features, natural history of evolution,
clinical outcomes and treatment responses. Yet, further research to define
the syndrome, its clinical stages and validation of neuroimaging,
Identification of mild and early subcortical dementia will enable new
therapeutic options.
SMALL VESSEL DISEASE WITHOUT DEMENTIA
Small vessel disease without dementia mostly presents as white-
matter lesions on MR imaging of brain. Such lesions of white matter
hyperintensity may occur as early as thirties, but their prevalence increases
strikingly with age and by 70 years of age almost 70% of the population
has such lesions. Frequently, white matter lesions are associated with
vascular risk factors. But oxidative stress is found to be a poorly
recognised risk factor for white-matter lesions. White-matter lesions are
implicated in causing important cognitive dysfunction even in the absence
of dementia.43,69,70 Some important non-cognitive and motor consequences
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include depression, gait disorder, imbalance, urinary frequency that often
impairs quality of dailyliving.71
SMALL VESSEL DISEASE AND ALZHEIMER’S DISEASE
Mixed dementia encompassing Alzheimer’s disease(AD) with small
vessel disease is a difficult concept. Although common, this coexistence is
not well recognised by current diagnostic methods. Degenerative and
vascular pathologies interact and manifest as cognitive impairment.72  AD
and small vessel disease share some common pathogenetic mechanisms.73
VASCULAR FACTORS IN ALZHEIMER’S DISEASE
          The evidence for cerebrovascular pathology in AD, including small-
vessel disease and microinfarction is considerable. This suggests a
substantial overlap between vascular dementia and AD. Amyloid
angiopathy is the most common pathologic vascular lesion in AD, present
in almost all AD cases. Apolipoprotein E4 is a strong factor associated
with the development of AD. It may cause cognitive dysfunction
independent of plaque load and tangle pathology. Yet, its exact role in non-
cognitive and cognitive features requires further clarification. Vascular risk
factors such as diabetes mellitus, hypertension, atherosclerosis, ischaemic
heart disease, smoking and raised homocysteine are also risk factors
commonly associated with AD  and biomarkers of systemic vascular
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disease like hypercholesterolaemia  are also associated with the
aetiopathogenesis of AD. These  vascular pathologies may result in
localised or global cerebral hypoperfusion brain that may inturn lead to
white-matter lesions, AD pathology  or both. Genetic factors like
apolipoprotein E can modify the progression of AD in the presence of
cerebrovascular disease. And hence, the prevention or treatment of
vascular risk factors may reduce occurrence of AD and mixed dementias.
None current criteria distinguishes alzheimer’s and mixed dementia. For
the most part, none of these criteria have been satisfactorily validated by
prospective study. Structural neuroimaging, especially MRI is the imaging
tool of choice to assess cerebrovascular disease, but functional brain
imaging is the potential instrument useful to differentiate AD with small
vessel disease from vascular dementia.
HEREDITARY DISORDERS WITH VASCULAR COGNITIVE
DYSFUNCTION
The genetic contribution to vascular dementia and stroke is
important. The genetic defects for numerous monogenic disorders are
identified. CADASIL is a monogenic cause of small-vessel disease
manifesting as white matter disorder and stroke in young individuals.
Clinical presentation may be transient ischaemic attacks and strokes
(80%), migraine with aura (40%), cognitive deficits (50%), epilepsy (10%)
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and psychiatric disorders (30%).74 Mean age of disease onset is in thirties
and neuroimaging may reveal small lacunar infarct and diffuse white-
matter lesions.75 The underlying pathovascular lesion is non-amyloid
angiopathy of small arteries and capillaries primarily involving the brain,
but also other organs. Diagnosis hence may be made by skin biopsy.
Microscopic examination shows granular osmiophilic deposits in the
vascular basal membrane. The disease is due to mutations in the NOTCH3
gene, that codes for a transmembrane receptor. CADASIL mutations
involves a highly conserved cysteine residues in the epidermal-growth-
factor   repeat  domains.  Expression  of  NOTCH3  is  always  restricted  to
vascular smooth-muscle cells. The cerebral amyloid angiopathies are
characterised by deposition of amyloid in the walls of leptomeningeal and
cortical blood vessels. Clinical manifestation includes multiple and
recurrent lobar haemorrhages resulting in cognitive deterioration and
strokes. MRI often displays focal lesions that may be ischaemic or
haemorrhagic as well as diffuse white-matter abnormalities. Blood vessels
show amyloid deposition, microaneurysm formation and fibrinoid
necrosis. Rupture of such structurally weakened vessels result in cerebral
haemorrhage, especially in the cortex (lobar haemorrhage) rather than the
subcortical regions like basal ganglia, thalamus that typical occur in
hypertensive haemorrhage.
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COGNITIVE AND PSYCHIATRIC SYMPTOMS
          Vascular cognitive impairment includes many diverse syndromes of
varied causes, with marked differences in clinical presentation and course.
Single  strategic infarcts may produce cognitive and other deficits which
entirely depend on the location  and size of the infarct. But, the
characteristic neuropsychological profile of small vessel disease is early
impairment of attention , executive dysfunction, slowing of motor
performance and information processing.76,77 Episodic memory is
relatively spared compared with AD. Other cognitive functions are also
affected variably, depending on the pathological substrate involved in
individual cases. The concept of amnestic cognitive impairment is
probably very limited because of early executive, attentional and motor
disabilty in patients with early vascular disease.
         The psychiatric profile of vascular cognitive impairment is not well
established but there exists a strong relation between small vessel disease
with  white-matter lesions and depression.  Another important factor is the
site of the ischaemic lesions  that involve the thalamocortical projections
that may predispose to depression. In vascular cognitive impairment, the
neurobiological substrates for the cognitive and psychiatric symptoms is
yet to be established. Attentional impairments, executive dysfunction,
slowed mentation and depression are probably due to disruption of
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frontosubcortical circuits. Small-vessel disease causing lacunae and white-
matter changes is likely to be the important pathological process resulting
in cognitive dysfunction. The relationship between the symptoms and
specific location of the lesion remains to be established. This information
is essential for the rational conceptualisation of these vascular disorders
and for developing targeted treatment. The variability of symptoms relate
to the site and extent of specific lesions.
         The contribution of white-matter changes as seen on MRI to the
clinical progression of disease is of great importance but it remains to be
established. In particular, progression of lesions is not yet clearly
correlated with worsening of cognitive function. 78 With current available
methods, more than 1 year follow-up is required to detect the progression
of white-matter changes and for selection of those patients at high risk of
disease progression.
PRIMARY PREVENTION
          Knowledge of pathophysiological mechanisms of the disease
process is essential to formulate any primary preventive measures. Since
small vessel disease of the brain may result from various pathological
processes, strategies for preventive measures vary accordingly. Small
vessel disease is only one of the manifestations of systemic processes that
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affect the blood vessels throughout the body. The pathophysiology in a
given individual that result in small vessel disease of the brain but not in
other organs is not well understood. Treatment of the primary risk factors
is essential, so that secondary changes and clinical disease can be
prevented. For instance, it is always better to prevent the occurance of
stroke by early and aggressive treatment of systemic hypertension than by
detecting and removing an established carotid atheroma. Early intervention
is important because the risk factors cause vascular injury in early life,
probably before the fourth decade. But it is difficult to intervene at this
stage because the early stages of vascular injury may remain clinically
silent.
          For primary prevention to be successful, these strategies must be
based on accurate identification of the pathological process that result in
vascular injury. Further, the pathophysiological mechanisms,  by which
small vessel disease of brain cause  cognitive dysfunction is to be
explored. But current strategies insist on early detection and adequate
treatment of known vascular risk factors.
SECONDARY PREVENTION
          Treatment of acute vascular event has attained major advances
especially with thrombolytic agents and antiplatelet drugs for ischaemic
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stroke. But the studies on the role of neuroprotective agents are
disappointing.79 Treatment  for  recurrent  episodes  of  stroke  is  now  well
studied and guidelines established82 that  include antiplatelet agents,
warfarin for atrial fibrillation, carotid endarterectomy for atherosclerotic
disease of carotids and adequate blood-pressure lowering. Eventhough the
data are limited, trials on recurrent stroke prevention tends to offer the
opportunity to investigate stroke-associated cognitive dysfunction and
dementia.
SYMPTOMATIC TREATMENT
           Several large, randomised, double-blind, controlled trials have
already been done. Initial studies of varied drugs including nootropics,
vasodilators and antioxidants in the treatment of vascular dementia are
disappointing.80 Adequate  evidence is available with other agents like
propentofylline and memantine  in symptomatic treatment of vascular
cognitive impairment.81 The calcium channel antagonist and vasodilator
nimodipine has been extensively studied. Studies have shown no overall
evidence of efficacy of nimodipine invascular AD but beneficial effects are
seen in patients with subcortical vascular dementia82 and further studies in
this area are continuing. Studies suggest evidence of efficacy for
cholinesterase inhibitors in vascular cognitive impairment. In a double-
blind, placebo-controlled trial with possible and probable vascular
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dementia, by NINDS-AIREN criteria, donepezil, a cholineesterase
inhibitor significantly improved cognitive function when compared  with
placebo.83  A study in patients with vascular cognitive dysfunction or AD
with cerebrovascular disease, 24 mg galantamine improved cognition
significantly when compared with placebo. Results from other trials are
awaited. But evidence so far suggests that cholinesterase inhibitors may be
of immense benefit in treating vascular dementia.
            Thus various literature has shown that hypertension and ageing are
the important risk factors for small vessel disease and understanding of its
pathogenesis is essential for devising newer therapeutic modalities and
drugs.
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MATERIALS AND METHODS
STUDY GROUP
The study was conducted on inpatients and out patients of Institute
of Neurology, Rajiv Gandhi Government General Hospital Chennai.
Approval from the hospital ethical committee was obtained. The study was
observational, cross sectional study in nature designed to analyse the
patients  in   age  group  of  40  years   and  above  ,  who presented  with  MRI
showing white matter changes in the periventricular or deep white matter
region.
The   sample  size  was  38  and  the  study  period  was  from  January
2010 to December 2012.
Inclusion criteria
1. Subjects symptomatic or asymptomatic with age more than 40yrs
2. MRI showing white matter changes in the periventricular or deep
white matter region
Exclusion criteria
1. Subjects with mini-mental score less than 9
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2. Subjects meeting DSM-IV or Alzheimers disease and related
disorders criteria for Alzheimers disease
3. Terminal illness
4. Major psychiatric illness
All subjects underwent a comprehensive higher mental function
evaluation including detailed lobar function. Attention was assessed by
Digit repition test- both digit forward and digit backward were  tested and
sustained attention assessed by “A” Random letter test. Comprehension,
repitition and spontaneous speech were assessed. Verbal Fluency was
tested by Animal-naming test and FAS test. Memory was tested by
applying Wechsler memory scale. Executive function was tested  by trail-
making test. Cognitive function was tested by fund of  knowledge,
Calculation,  Problem solving,  Social awareness and Judgement and
Abstract thinking by Proverb interpretation .
           MRI white matter changes were assessed by Fazekas visual rating
scale.
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Fazeka visual rating scale
Scoring for Periventricular hyperintensities (PVH)
Absence - 0
Caps  or pencil-thin lining -1
Smooth "halo" -2
Irregular PVH extending into the deep white matter -3
Deep white matter hyperintense signals (DWMH)
Absence -0
Punctate foci -1
Early confluence of foci -2
Large confluent areas -3
A total score of  0 to 2 was taken as mild, score of 3 and 4 taken as
moderate and score of  5 and 6 is taken as severe. All patients underwent a
thorough clinical examination and assessed for focal neurological deficit.
Obtained data were tabulated statistical analysis done by IBM-SPSS
statistical software.
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RESULTS AND ANALYSIS
Cognitive dysfunction in patients with small vessel disease as
manifested on MRI as white matter changes was studied. MRI changes
were rated by Fazekas scale. Various cognitive domains were assessed by
clinical methods and whether cognitive dysfunction correlated with
severity of MRI white matter changes was studied. The results are as
follows.
EPIDEMIOLOGY
Total number of subjects studied with MRI white matter changes
was 38.
Table -1- Age Distribution
Cases
No Percentage
40-50 7 19
50-60 8 21
60-70 19 47
>70 3 13
38
In the present study, patients age ranges from 40-77 years.  Most of
the patients were in the age group  of 60-70, which was about 47% of the
total number of cases.
Table -2 Sex Distribution
Sex
Cases
No Percentage
Male 26 68%
Female 12 32%
Out  of  the  38  patients  studied,  68%  were  male  and  32%  were
female.
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Table -3 Risk factor profile
Male
Total-
26
Percentage
Female
Total -
12
Percentage
Total
percentage
Hypertension 17 65 5 42 57
Diabetes 14 54 6 50 53
Smoker 20 77 0 0 53
Dyslipidemia 9 35 3 25 32
 Hypertension, Diabetes, smoking and dyslipidemias were found in
significant number of patients. Among the non-modifiable risk factors,
hypertension(57%)  was the most prevalent risk factor found in patients
with white matter changes. Smoking was the modifiable risk factor present
in 53% of the study population who were all men.
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Table-4 EEG Profile
Number of Patient Percentage
Normal 29 76
Focal slowing 1 3
Diffuse slowing 8 21
Among the patients with white matter changes, twenty nine (76%)
had normal EEG. Eight patients(21%) had diffuse slowing on EEG.
 MRI white matter changes were scored by Fazekas scale and the
number of patients with different scores are as follows.
Out of the 38 subjects studied, 8% had a score of 1, 24% had a score
of 2, 32% had a score of 3, 21% had a score of 4, 10% had a score of 5, 5%
had a score of 6. Most of the subjects had a score of 3.
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Table -5  Fazeka Score Profile
Fazekas score Number of patients Percentage
1 3 8
2 9 24
3 12 32
4 8 21
5 4 10
6 2 5
Table- 6 Severity Grading – Fazekas Scale
Severity grade Number Percentage
Mild 12 32
Moderate 20 52
severe 6 16
Out of 38, 52% of patients, came in the category of moderate score of
Fazeka rating scale.
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Table- 7 Cognitive Dysfunction In Various Domain
Domain Number of patients Percentage
Executive Dysfunction 15 39
Attention 14 37
Alternate Sequence 15 39
Fluency 13 34
Psychomotor slowing 21 55
Memory 8 21
Higher Cognition 18 47
Among the 38 patients with white matter changes, 14 (37%) had
normal function in all cognitive domains, whereas 24(63%) patients had
dysfunction in one or more cognitive domains.  Out of the thirty-eight
patients with white matter changes, most common higher mental function
disturbance was psychomotor slowing(55%). Memory was the least
affected parameter(21%). Higher cognitive function was also significantly
affected(47%). Attention (37%), Alternate sequence(39%) were also
significantly affected.
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Table - 8 Attention and MRI grading
MRI changes
Attention deficit
Number of patients Percentage
Mild 3 21
Moderate 6 43
severe 5 36
                          Total 14 37%
Attention assessed by Digit Repetition Test and Random ‘A’ Letter Test
was affected in fourteen(37%). Among them 43% had moderate white
matter changes, 36% had severe white matter changes and 21% had mild
white matter changes.
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Table -9 Executive Dysfunction and MRI grading
MRI changes
Executive Dysfunction
Number of patients Percentage
Mild 4 27
Moderate 5 33
severe 6 40
                          Total 15 39%
               Executive dysfunction as tested by trail making test was impaired
in 39% of subjects. Among them 40% had severe white matter changes,
33% had moderate white matter changes and 27% had mild white matter
changes.
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Table -10 Alternate Sequence and MRI Grading
MRI changes
Alternate sequence
Number of patients Percentage
Mild 1 7
Moderate 9 60
severe 5 33
                          Total 15 39%
Out of the 38 subjects investigated, 39% had impairment in alternate
sequencing. Among them 60% had moderate white matter changes, 7%
and 33% had mild and severe white matter changes respectively.
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 Table – 12 Fluency and MRI Grading
MRI changes
Fluency Impairment
Number of patients Percentage
Mild 1 8
Moderate 7 54
severe 5 38
                          Total 13 34%
               Fluency tested by Animal naming test and FAS test was impaired
in 34% of subjects. Among them, 54% had moderate white matter changes,
38% had severe white matter changes and 8% had mild white matter
changes.
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Table – 13 Psychomotor Slowing and MRI grading
MRI changes
Psychomotor slowing
Number of patients Percentage
Mild 3 14
Moderate 12 57
severe 6 29
                          Total 21 55%
Out of the 38 subjects investigated, 55% had impairment in alternate
sequencing. Among them 57% had moderate white matter changes, 29%
and 14% had severe and mild white matter changes respectively.
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Table -14 Memory Impairment and MRI grading
MRI changes
Memory Impairment
Number of patients Percentage
Mild 0 0
Moderate 2 25
severe 6 75
                          Total 8 21%
Memory was tested Weschler memory scale and was impaired in
21%  of  patients. Among them, 75% had moderate white matter changes,
25% had moderate white matter changes.
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Table – 15 Higher Cognition and MRI grading
MRI changes
Higher cognitive impairment
Number of patients Percentage
Mild 2 11
Moderate 12 67
severe 4 22
                          Total 18 47%
Higher Cognitive function was tested by Fund of  knowledge, Calculation,
Problem solving,  Social awareness and Judgement and Abstract thinking
by Proverb interpretation. In the study population, 18(47%) had higher
cognition impairment, of which 11% had mild, 67% had moderate and
22% had severe MRI white matter changes.
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DISCUSSION
RajivGandhi Government General Hospital and Research Centre,
Chennai is a premier institute and referral centre of southern India. Patients
refered for various reasons, with MRI showing white matter
hyperintensities were studied for cognitive dysfunction and correlation
between severity of white matter changes and cognitive deterioration  was
analysed.  Total of 38 patients were studied. This is a cross sectional study
done between
Population Characteristics and Risk Profile
          Analysing the age group in this study, maximum white matter
changes were seen in the age group of 60-70 years(47%).  The prevalence
of white matter lesions increased with  age, rising from 19% among 40  to
50year-old subjects to 47% among 60- to 70-year-old subjects. This higher
prevalence rate compared to the younger age groups  show, age is an
important risk factor for white matter disease. Though the prevalence in
age group > 70years was lesser, it could be due to higher morbidity
associated with increasing age, as sick patients with lesser MMSE and
bedridden patients were excluded from the study. Breteler et al’s 84 study
has shown that increasing age is an important risk factor for cerebral white
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matter disease. Similar results were obtained in study by Awad et al5 and
Kertesz et al85
In our study 68% of the patients were male which shows significant
male preponderance of white matter disease in male. This is in contrast
with  the  study  by  sullivan  et  al 86 which shows higher prevalence in
female(60%). Reinhold schmidt’s study87 also shows slight preponderance
in female(female:male = 51:49)
Table – 16 comparison of sex distribution
Sex Our study Sullivan et al Schmidt et al
Male 68% 40% 49%
Female 32% 60% 51%
              Analysing the risk factors associated with white matter changes,
Hypertension was the most common modifiable risk factor. Smoking was
the most common non-modifiable risk factor and it had the strongest
positive association with small vessel disease causing white matter lesions.
Schmidt et al case control study with 89 patients, also confirmed previous
results demonstrating a higher rate and extent of areas of WMH in
hypertensive subjects compared with controls.5,87,88
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Diabetes mellitus was presesent in more than 50 percent of patients
in both male amd female. Study by Breteler43 found no  evidence for a
relation between diabetes mellitus and white matter lesions.
           In our study, dyslipidemia was present in significant number of
patients(31%). Bretelers43 study   showed that  total  cholesterol   and  HDL
cholesterol levels were not significantly associated with the presence of
white matter  lesions  among all  subjects combined. However, for subjects
of  elderly  age  group  of  65  to  74  years  of   age,  higher   levels  of   total
cholesterol tended  to be associated with white matter lesions.
Analysis MRI white matter lesions
       White matter changes in MRI were scored from 1-to 6 by Fazekas
scale. In our study, score of 3 was found in most number of parients32%.
Score of 2 and 4 was seen in 24% and 21% respectively. White matter
lesions were sub classified as mild, moderate and severe. Moderate score
was the most prevalent sub-group among the patients(52%). In comparison
to our study, Zimmerman et al showed score of 1(43%) and 2(29.9%) were
the most common patterns.
           Van Den Heuvel on behalf of PROSPER study group, analysed the
reliablity of visual scoring system in comparison with volumetric methods.
He concluded that, reliablity of visual scoring system was good but
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volumetric analysis in more sensitve and objective method to study
longitudinal white matter changes.
Analysis of cognitive profile
In our study 28 patients(74%) had cognitive dysfunction in various
domains and 10 patients(26%) had normal cognitive function. Among the
asymptomatic patients, mild score on MRI was the most prevalent(64%).
In symptomatic patients with impaired cognition, moderate scored lesions
were most prevalent(62.5%)
Normal cognition = 10(26%) Cognitive impairment =28(74%)
Mild 8 80% Mild 4 14%
Moderate 2 20% Moderate 18 64%
Severe 0 Severe 6 22%
Specific Cognitve Dysfunction
Psychomotor slowing was the most prevalent cognitive domain
affected in symptomatic patients. It was observed in 55% of patients.
Executive dysfunction and impairment in alternate sequence was found to
be abnormal in 39% each. Higher cognition was impaired in 47% of
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patients. Memory was least affected, seen in 21% of patients. Multiple
cognitive domain impairment was seen commonly in patients with small
vessel disease presenting as white matter changes because the fronto-
subcortical fibres for multiple cognitive function are present clustered in
the periventricular region.
In our study, psychomotor slowing and executive dysfunction were
the two most affected domains.
          Amberla et al89 study of small vessel disease in genetically mediated
conditions like CADASIL showed early impairment of Executive fuction
and later deficits in mental speed and set-shifting abilities.
         Case  -  control  study  by  Cohen  et  al90 showed that executive
dysfunctions and attention impairment were strongly associated to the
presence and extension of Subcortical hyperintensities.
           Kramer et al’s91 study also showed executive dysfunction as the
earliest and most common domain affected.
In  concordance  with  our  study,  Prins  et  al92 in a population based
study, concluded that  measures of small vessel disease by MRI  associated
with cognitive decline in executive functions and processing speed.
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          Skoog et al93 in his case control study concluded that white matter
lesions correlated with general and specific cognitive domains  like
visuospacial orientation and processing speed.
          In another study, Wen et al94 inferred that white matter lesions but
not lacunar infarcts correlated with impaired executive tests.
         On analysing the severity of MRI changes with cognitive
dysfunction, positive correlation existed between the two. Of the subjects
with severe white matter changes, all of them had cognitive dysfunction in
one or other domains. Of all the domains analysed, Psychomotor slowing
and  Higher Cognition were the two domains severely involved and their
involvement correlated with severity of MRI white matter changes. Other
domains like attention, alternate sequence, fluency also had positive
correlation with MRI changes. Memory was the domain least involved in
the our study population and it did not have positive correlation with MRI
changes.
          In concordance with our study, Cohen et al’s90 study has shown that
executive dysfunction correlated with sub-cortical hyperintensity volume.
     De groot et al’s95 population based study showed positive correlation
between periventricular white matter hyperintensity and decline in
cognitive function. Kramer et al91 and Logan et al studies also shown that
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extent white matter hyperintensity correlated with severity of cognitive
dysfunction.
In contrast, De mendonca et al96 and sabri et al97 study have shown
that white matter lesions were not correlated with cognitive dysfunction.
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CONCLUSION
1. Asymptomatic subclinical cognitive dysfunction occur in cerebral
small vessel disease manifesting as white matter hyperintensity.
2. Age is strong risk factor for small vessel disease and increasing age
is associated with severe white matter changes and higher decline in
cognitive function.
3. Psychomotor slowing was observed most commonly in patients with
small vessel disease. Reaction time, paradigms to be done for further
confirmation.
4. Impairment of Higher cognition like judgement, abstract thinking
were observed in patients with small vessel disease.
5. Frontal lobe battery revealed Attention, alternate sequence,
executive function and verbal fluency were also significantly
impaired in small vessel disease.
6. Memory was least affected cognitive domain in small vessel disease.
7. Psychomotor slowing and higher cognitive dysfunction correlated
the best with MRI white matter changes, though statistical
significance could not be established in view of small cohart.
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Thus, MRI white matter changes are considered as surrogate marker
of cerebral small vessel disease. Patients with white matter changes had
asymptomatic cognitive dysfunction involving various domains which is
found to increase with increasing age. Progressive cognitive dysfunction
leads to impairment of activities of daily living and moreover, small vessel
disease is also risk factor for cerebrovascular accidents. Hence, the
conditions that predispose to cerebral small vessel disease has to be
checked to prevent cognitive dysfunction. Active treatment options are not
available as on date for small vessel disease, hence preventive measures
are essential. More studies are needed in small vessel disease to further
understand its pathophysiology and to device new treatment modalities.
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FIG-7 COGNITIVE PROFILE IN RELATION TO MRI 
 
PATIENT  CONSENT  FORM 
 
STUDY TITLE : A STUDY ON ACUTE  SYMPTOMATIC SEIZURES  IN  THE     
ELDERLY 
Study Centre  : Madras Institute of Neurology, 
                                                          Madras Medical College, Chennai – 600 003 
Patient’s Name  : 
Patient’s Age  : 
Identification Number  :                Patient may check ( ) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I 
have the opportunity to ask the question and all my questions and doubts have been 
answered to my complete satisfaction. 
 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving any reason, without my legal rights being 
affected. 
 
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethics committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
study. I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that arise from this 
study. 
 
I agree to take part in the above study and to comply with the instructions given 
during the study and to faithfully co-operate with the study team, and to 
immediately inform the study staff if I suffer from any deterioration in my health or 
well being or any unexpected or unusual symptoms. 
 
I hereby consent to participate in this Study on  acute symptomatic seizures in the 
elderly 
 
I hereby give permission to undergo complete clinical examination and diagnostic 
tests including hematological, biochemical, radiological and urine examination. 
 
Signature / Thumb Impression ___________________ Place _________ Date ____________ 
Patient’s Name and Address: ___________________________________________________ 
Signature of the Investigator : ___________________ Place _________ Date ____________ 
Study Investigator’s Name : ________________________________________________ 
                                                  PROFORMA 
 
Cognitive Dysfunction In Patients With Small Vessel 
Disease  
 
1. Patients name 
2. Age  
3. Sex 
4. Phone number 
5. Education  
6. Occupation 
7. Family h/o stroke 
8. Hypertension 
9. Diabetes mellitus 
10. Dyslipidemia 
11. Alcoholic 
12. Smoker  
13. Symptoms  
14. Headcahe                                              nausea/vomiting 
15. CN symptoms 
16. Limb weakness 
17. Seizures  
18. Altered consciousness 
19. Amotivation 
20. Self care 
21. Memory disturbance 
22. Way-finding difficulty 
23. Hallucinations  
 
Weight  
BP 
Peripheral disease 
Renal disease 
Cardiac disease 
Cranial nerves 
 
Limb weakness 
 
MMSE 
Digit span 
3-7 
7-4-9 
8-5-2-7 
2-9-6-8-3 
5-7-2-9-4-6 
8-1-5-9-3-6-2 
3-9-8-2-5-1-4-7 
Random letter test 
L   T   P   E   A   O   A   I   C   T    D   A   L   A   A 
A   N   I   A   B   F   S   A   M   R   Z   E   O   A   D 
P   A   K   L   A   U   C   J   T   O   E   A   B   A   A 
Z   Y   F   M   U   S   A    H   E   V   A   A   R   A   T 
Verbal fluency 
FAS test 
Animal naming 
Wechsler memory scale 
Constuctional ability 
Alternate visual pattern completion test 
Alternating motor pattern test 
Addenbrooks cognitive scale 
Lobar function test 
Investigations 
Hemoglobin 
FBS/PPBS 
Urea 
Creatine 
Complete lipid profile 
CXR 
ECG 
EEG 
MR Imaging 
Fazekas visual rating scale  
 
 
 
  
                                       KEY TO MASTER CHART 
SEX 
       M-male  ,  F-female 
Diabetes mellitis : 1- present,  2- absent    
Systemic hypertension: 1- present,  2- absent    
Smoker :   1- yes,  2- no 
Dyslipidemia : 1- present,  2- absent    
Attention :  1 – Impaired, 2- normal 
Executive dysfunction : 1 – Impaired, 2- normal 
Alternating sequence : 1 – Impaired, 2- normal 
Memory :  1 – Impaired, 2- normal 
Fluency : 1 – Impaired, 2- normal 
Psychomotor slowing : 1 – Impaired, 2- normal 
MRI BRAIN – fazekas visual rating scale 
1-mild, 2 – moderate, 3- severe. 
 
       
 
s.no Age Sex DM HT Dyslipidemia Alcohol Smoker EEG
1 46 2 1 2 1 2 2 1
2 53 1 1 1 2 1 1 1
3 48 1 2 1 1 2 2 1
4 66 1 1 1 2 2 1 1
5 71 1 1 1 2 2 1 2
6 52 2 2 1 2 2 2 1
7 59 2 1 1 2 2 2 1
8 68 1 2 2 2 2 2 3
9 76 2 2 2 1 2 2 1
10 43 1 2 1 2 1 1 1
11 57 1 1 1 2 2 2 3
12 63 2 1 1 2 2 2 1
13 59 1 1 1 1 1 1 1
14 47 1 1 2 2 2 2 1
15 67 1 2 1 1 2 1 3
16 54 1 1 1 2 2 1 1
17 49 2 2 1 1 2 2 1
18 56 2 1 1 2 2 2 3
19 74 1 2 1 2 2 2 1
20 58 2 2 2 2 2 2 1
21 46 1 1 2 1 1 1 1
22 61 1 2 1 2 2 2 1
23 54 2 1 2 2 2 2 3
24 55 1 1 1 1 1 1 1
25 54 1 1 2 2 2 1 1
26 75 1 2 2 2 2 1 1
27 56 1 1 1 1 2 1 1
28 47 2 2 2 2 2 2 3
29 51 1 2 1 2 1 1 1
30 67 1 2 2 2 2 1 1
31 58 1 1 1 2 2 1 1
32 54 2 2 2 2 2 2 1
33 66 1 1 1 1 1 1 3
34 58 2 2 2 2 2 2 1
35 72 1 1 2 1 1 1 1
36 55 1 2 2 2 2 1 1
37 63 1 2 1 2 1 1 3
38 56 1 1 2 1 1 1 1
Attention Executive functionAlt sequence FluencyPs chomotor slowingMemoryHigher CognitionMRI score
2 2 2 2 1 2 2 2
1 1 1 2 1 2 2 1
2 2 2 2 2 2 2 2
2 1 2 2 1 1 1 3
2 2 2 2 2 2 2 1
2 2 1 1 2 1 2 2
2 2 1 2 2 2 2 2
1 1 2 1 1 2 1 1
2 2 1 1 2 2 1 2
2 2 2 2 2 2 2 1
2 2 2 2 2 2 2 2
1 1 1 1 1 1 1 3
2 2 2 2 2 2 2 1
2 2 1 2 1 2 1 2
2 2 2 1 2 2 1 2
1 1 1 1 1 1 1 3
2 2 2 2 2 2 2 1
1 1 1 2 1 2 1 2
2 2 2 2 1 2 1 2
1 1 1 1 1 1 2 3
2 2 2 2 2 2 2 1
2 2 2 2 1 2 1 2
1 1 1 1 1 2 1 2
2 2 2 2 2 2 2 1
1 1 1 1 1 1 2 3
1 1 2 2 1 2 2 1
2 2 2 2 2 2 2 1
2 2 2 2 2 2 2 2
2 1 2 2 2 2 1 1
1 1 1 1 1 1 1 3
2 2 2 2 2 2 2 1
2 2 2 2 1 2 1 2
1 1 1 1 1 2 2 2
1 2 2 2 2 2 1 2
2 1 1 1 1 2 2 2
2 2 2 2 1 2 1 2
1 1 1 1 1 1 1 2
1 2 2 2 1 2 1 2
